Lessons from the scale-up of provider-administered and self-injection of DMPA-SC in Nigeria: a landscape assessment.

Background: Nigeria is the seventh-most populous country in the world. Its high fertility rate and unmet need for family planning contribute to the increasing population size. To reduce this gap, the Federal Government of Nigeria, in collaboration with Injectables Access Collaborative and other public and private sector players, introduced the subcutaneous depot medroxyprogesterone acetate (DMPA-SC) to the contraceptive method mix in 2017.

Influence of Movement Restriction During the COVID-19 Pandemic on Uptake of DMPA-SC and Other Injectable Contraceptive Methods in Nigeria.

Introduction: The COVID-19 pandemic caused significant disruptions to sexual and reproductive health (SRH) services globally, with a pronounced impact on low- and middle-income countries like Nigeria. This study investigates how COVID-19 travel restrictions influenced the uptake of depot medroxyprogesterone acetate subcutaneous (DMPA-SC) and other injectable contraceptives in Nigeria.

Methods: This study analyzed 26 months of secondary logistics data from the national electronic Health Logistics Management Information System (e-HLMIS), covering 36 states and encompassing periods before, during, and after the implementation of travel restrictions.